CORONA Remedies Limited announced its unaudited financial results for the second quarter and half year ended September 30, 2025, following approval by its Board of Directors. The company reported strong growth across both revenue and profitability, outperforming overall market trends.
For the second quarter of FY26, CORONA Remedies recorded year-on-year revenue growth of 15.1%, while revenue for the first half of FY26 increased by 17.0% compared to the corresponding period last year. Profit after tax rose by 21.8% in Q2 FY26 and by 35.1% in H1 FY26, reflecting improved operating leverage and sustained margin performance. The company also maintained healthy return ratios during the period.
Commenting on the results, Nirav K Mehta, Managing Director and Chief Executive Officer, said the performance reflects consistent execution of the company’s strategy and a sharp focus on its core therapeutic segments. He highlighted continued investments in strengthening the field force, expanding the brand portfolio, and deepening engagement with specialist doctors as key contributors to growth.
Mr Mehta also acknowledged the role of banking partners in the successful listing of CORONA Remedies on Indian stock exchanges and expressed appreciation for the continued support of employees and stakeholders.
Founded in 2004, CORONA Remedies is an India-focused branded pharmaceutical formulations company with a presence across women’s healthcare, cardio-diabeto, pain management, urology, and other therapy areas. The company manufactures its products at a WHO-GMP and EU-GMP certified facility, ensuring compliance with international quality standards.
CORONA also operates two DSIR-approved research and development centers with a team of more than 100 professionals, including scientists engaged in new formulation development. With a workforce of over 4,500 employees, the company continues to build a strong foundation for sustainable long-term growth in the Indian pharmaceutical market.
